Shrinks In Sneakers

Tag: Antidepressant

  • Post-SSRI Sexual Dysfunction (PSSD): An Emerging Concern

    Post-SSRI Sexual Dysfunction (PSSD): An Emerging Concern

    Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), have been a cornerstone of treatment for mood and anxiety disorders for decades. However, as their use has become more widespread, concerns about their side effects—particularly those related to sexual health—have grown. A new wave of attention has focused on Post-SSRI Sexual Dysfunction (PSSD), a phenomenon in which sexual side effects persist even after the discontinuation of SSRI medications.

    What is PSSD?

    It is well-established that up to 50% of patients taking SSRIs experience some degree of sexual dysfunction while on the medication. These effects are usually thought to be transient, resolving within weeks or months after stopping the drug. However, PSSD represents a different and more troubling pattern: persistent sexual dysfunction lasting three months or longer after discontinuing the medication.

    Patients with PSSD frequently report symptoms such as:

    • Genital anesthesia (reduced or absent genital sensation).
    • Anorgasmia (inability to achieve orgasm).
    • Loss of libido (reduced or absent sexual desire).

    In men, erectile dysfunction and ejaculatory issues are common, while women often report reduced arousal and difficulty achieving orgasm. Unlike transient sexual dysfunction, the hallmark of PSSD is its persistence long after the drug has been stopped.

    The Challenge of Evidence

    The evidence supporting PSSD as a formal diagnosis remains limited and primarily consists of:

    • Case reports
    • Case series
    • Observational data, often derived from internet forums and patient advocacy groups

    While these sources highlight distressing patient experiences, they fall at the bottom of the evidence hierarchy. Without randomized controlled trials or large-scale cohort studies, it is impossible to definitively establish causation between SSRI use and PSSD. This lack of robust evidence complicates efforts to understand the true prevalence, biological mechanisms, and risk factors for PSSD.

    Potential Biological Basis

    The exact mechanism of PSSD remains unclear, but hypotheses include:

    1. Serotonin neurotoxicity: Excessive serotonin signaling may lead to long-lasting changes in the central or peripheral nervous systems.
    2. Dopamine suppression: Chronic serotonin elevation may inhibit dopamine pathways, which play a critical role in sexual function.
    3. Receptor desensitization or downregulation: Long-term SSRI use may alter serotonin and other neurotransmitter receptors in ways that persist after discontinuation.

    None of these theories have been definitively proven, and more research is needed to uncover the underlying pathophysiology.

    Prevalence and Diagnosis

    The true prevalence of PSSD is unknown due to the lack of large, high-quality studies. However, anecdotal reports suggest it may be rare but severely impactful for those affected.

    Currently, there are no standardized diagnostic criteria for PSSD. The most common approach involves:

    1. A history of SSRI use.
    2. Persistent sexual dysfunction lasting three months or more after discontinuing the medication.
    3. Symptoms such as genital anesthesia or nipple insensitivity, which are more specific to PSSD compared to general sexual dysfunction.

    What to Do if You Suspect PSSD

    For clinicians and patients encountering persistent sexual dysfunction, it’s essential to first explore modifiable and reversible causes of sexual dysfunction:

    • Lifestyle factors: Obesity, smoking, poor cardiovascular health, and sedentary behavior can contribute to sexual dysfunction.
    • Endocrine issues: Low testosterone or other hormonal imbalances should be evaluated.
    • Medications: Drugs such as finasteride (for hair loss) and isotretinoin (for acne) are also associated with persistent sexual dysfunction and may confound the diagnosis.

    If PSSD remains the primary suspected diagnosis, a timeline of symptoms is crucial. Note when the antidepressant was started, when sexual dysfunction began, and whether the symptoms improved or worsened after stopping the drug.

    The Bottom Line

    PSSD is an evolving area of concern in psychiatry and pharmacology. While current evidence does not definitively prove a causal relationship between SSRIs and persistent sexual dysfunction, the growing number of reports warrants further investigation. Until higher-quality studies emerge, clinicians should approach this condition with empathy and caution.

    Patients experiencing sexual dysfunction should work closely with their healthcare providers to rule out reversible causes and explore management options. For now, the best strategy is awareness, vigilance, and a patient-centered approach to treatment planning.

  • When Expectations Matter: Antidepressant Efficacy vs. Psilocybin’s Unique Impact

    When Expectations Matter: Antidepressant Efficacy vs. Psilocybin’s Unique Impact

    It’s always valuable to challenge our own assumptions, especially in areas as complex as mental health treatment. A secondary analysis of a randomized controlled trial, recently published in JAMA Psychiatry, explored the role of treatment expectancies in the efficacy of psilocybin versus escitalopram for depression.

    I’ve often argued that blinding these studies is challenging, and participants are likely to have higher expectations for psychedelics like psilocybin. However, this analysis provides a nuanced perspective.

    While participants did report higher expectations for psilocybin’s effectiveness compared to escitalopram, expectancy only seemed to impact outcomes in the escitalopram group. A stronger belief in escitalopram’s efficacy correlated with better results for those receiving it. In contrast, expectancy didn’t significantly influence psilocybin’s effectiveness.

    Another intriguing finding: individuals with higher pre-treatment suggestibility showed more significant therapeutic responses to psilocybin—a pattern not observed in the escitalopram group.

    Although this is a secondary analysis and not the final word on the topic, it raises fascinating questions. Could psilocybin’s therapeutic mechanisms be less reliant on patient expectations than traditional antidepressants?

    For now, this remains an open question, but I’ll be closely following future research as it unfolds.

    Link to article: https://pubmed.ncbi.nlm.nih.gov/39653344/

  • Gepirone: A New Player in the Antidepressant Arena—Should We Care?

    Gepirone: A New Player in the Antidepressant Arena—Should We Care?

    Gepirone may have flown under the radar for many of us. I’ll admit, it didn’t generate much excitement on my end. However, it recently crossed a significant milestone: FDA approval as an antidepressant. But let’s not overlook its rocky path to getting there—a journey marked by hurdles and setbacks.

    The road to FDA approval for gepirone was anything but smooth. Its initial development began decades ago, but the approval process faced repeated delays and rejections. Questions about efficacy and study designs kept it in limbo for years. What ultimately got it across the finish line was a re-analysis of data demonstrating robust effects in specific populations, particularly those with significant depressive symptoms. This serves as a reminder that persistence and rigorous data reassessment can change the trajectory for medications once thought to have limited potential.

    Now that gepirone is finally available, the big question is: should we care? If so, where does it fit into our treatment algorithms for adult depression?

    With a mechanism targeting the serotonin 1A receptor as a partial agonist, gepirone offers a unique profile compared to SSRIs, SNRIs, and other standard antidepressants. Its anxiolytic effects may make it particularly appealing for patients with co-occurring anxiety. However, like any medication, it isn’t without its downsides.

    Potential side effects include nausea, dizziness, fatigue, and headache. These are generally mild, but it’s important to monitor for tolerability in sensitive patients. Gepirone also carries warnings about potential interactions with other serotonergic agents, raising the risk of serotonin syndrome. While this risk isn’t unique to gepirone, it’s a critical point to keep in mind when integrating it into a treatment plan.

    So, where does gepirone fit? Will it serve as a first-line option for certain patients, or will it find a niche role for those with specific tolerability issues or suboptimal responses to other antidepressants?

    I’d love to hear your thoughts. Is gepirone a tool worth adding to our arsenal, or just another option that might not shift the needle much in clinical practice?

  • Olanzapine Fluoxetine Combination Symbyax: The OG of Bipolar Depression Treatment 

    Olanzapine Fluoxetine Combination Symbyax: The OG of Bipolar Depression Treatment 

    Introduction

    The olanzapine fluoxetine combination was FDA approved in 2003 for the treatment of depressive episodes in bipolar I disorder. In 2009 it was granted approval for treatment resistant depression. 

    This medication consists of the atypical dopamine blocking medication olanzapine and the SSRI fluoxetine. Many people consider olanzapine to be the best antipsychotic not named clozapine (see my video on the best antipsychotic in the world). This comes from the CATIE study where olanzapine proved to be superior to other medications. It has good efficacy, once daily dosing at night, and low risk for cardiac conduction abnormalities (QTc prolongation). However, the side effects including risk for weight gain and metabolic complications have made it a second line option. 

    My residents often jump to this medication on the inpatient unit, but I usually tell them to use caution because of the side effects and should it not be effective, it leaves you with clozapine as the next option in terms of effectiveness. 

    Fluoxetine is an antidepressant that has been around a long time with a broad spectrum of indications. It’s long track record and safety profile makes it a go to antidepressant in both the adult and child adolescent populations. Its main disadvantage is drug interactions. 

    Dosing

    People often think you can make this medication by simply combining olanzapine and fluoxetine and do not believe you need to use the brand name combination pills. I would use some caution with that approach. 

    When we look at the doses in the combination pill, they are ones that are difficult to make with the current available dosages. For example, olanzapine comes in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and finally 20 mg doses. 

    The fixed-combination capsule (olanzapine/fluoxetine) comes in 3/25 mg, 6/25 mg, 12/25 mg, 6/50 mg, 12/50 mg. The studies leading to approval of this medication were conducted using these doses in a fixed combination. It’s not clear that dosing each individually is effective. 

    How to Start the Medication

    For bipolar depression the olanzapine fluoxetine combination should be started at 6/25 mg dosed at bedtime. With a target dose of 6-12/25-50 mg depending on clinical response. 

    Labs prior to starting the medication: 

    You should have a baseline weight, waist circumference, blood pressure, fasting glucose and lipid profile prior to starting the medication 

    Cost

    The combination pill is more expensive than either medication alone. According to Good Rx The 6/25 mg capsule is $140-$150 per month. This is compared to olanzapine 5 mg which costs $9.00 and fluoxetine 20 mg which costs $4.00 

    Side Effects

    Olanzapine: Most common is somnolence (dose related), dry mouth (dose related), constipation (anticholinergic), weight gain (up to 40% incidence and 10-30 lbs. of weight gain is common), increased appetite, EPS (dose related). 

    Fluoxetine: Nausea, diarrhea, nervousness, abnormal dreams, weight loss, sweating, tremor, sexual side effects, rash, and headaches. Rare increased risk for bleeding when combined with NSAIDs and hyponatremia in the elderly due to SIADH. 

    Mechanism of action 

    Olanzapine: Dopamine D-2 and 5-HT2A antagonist that is metabolized by CYP1A2 and CYP2D6 

    Fluoxetine: serotonin reuptake inhibitor that is metabolized by CYP2D6 and is an inhibitor of CYP 2C9/2C19 and 2D6 with a half-life of 4-6 days and 9 days for the metabolite norfluoxetine 

    The half-life is important here because what happens when someone stops taking the medication? The olanzapine has a much shorter half-life and will be cleared from the body more rapidly leaving the person exposed to fluoxetine without a mood stabilizing element possibly inducing mania or worsening mood symptoms. This is something to be mindful of when using this combination. 

    Studies Showing Efficacy

    The studies that resulted in FDA approval for bipolar depression in 2003 were short, 8 weeks in duration. A total of 833 patients with bipolar I depression received either olanzapine alone, olanzapine fluoxetine combination (OFC), or placebo. Patients on OFC and olanzapine alone showed a significant reduction in depressive symptoms compared to placebo as early as the end of week 1 of treatment. By the end of 4 weeks the OFC participants saw significantly more improvement than placebo or olanzapine alone. The superiority continued over the final 4 weeks of the study. By the end 24.5% of patients on placebo met remission criteria, 32.8% of the olanzapine only group achieved remission, and 48.8% of the OFC group achieved remission. 

    For the 2009 approval of OFC in treatment resistant depression, it was based off two eight-week double blind placebo-controlled studies using doses of 6 to 18 mg for olanzapine and 25 to 50 mg for fluoxetine. 40% of patients receiving the OFC responded to therapy Vs 30% and 26% receiving fluoxetine or olanzapine monotherapy. The starting dose was 6/25 mg and could be titrated to 18/75 mg as tolerated. 

  • Unintended Outcomes After FDA Pediatric Antidepressant Warnings

    Unintended Outcomes After FDA Pediatric Antidepressant Warnings

    The article “Intended and Unintended Outcomes After FDA Pediatric Antidepressant Warnings: A Systematic Review” examines the effects of the FDA’s 2003-2004 black box warning on antidepressants regarding the risk of increased suicidal thoughts and behaviors in children and adolescents.

    Intended Outcome:

    • The FDA issued the warning to ensure greater awareness of potential risks, encouraging careful monitoring of pediatric patients taking antidepressants.
    • The goal was to reduce suicidal behaviors potentially linked to antidepressant use in younger populations.

    Unintended Outcomes:

    • The warning led to a significant drop in antidepressant prescriptions for children and adolescents.
    • There was a corresponding increase in untreated depression, which may have led to higher rates of suicide attempts and worsening mental health outcomes in some cases.
    • Reduced prescriptions were associated with a decrease in diagnosis and treatment of mood disorders in pediatric populations.
    • The warning inadvertently caused confusion among healthcare providers and parents, often resulting in delays in seeking treatment for depression or anxiety.

    Post-Warning Trends:

    • Follow-up research found no consistent evidence that the use of antidepressants in pediatric patients increases the risk of completed suicides.
    • The decline in antidepressant use and increase in suicidal behaviors during the period following the warning suggest unintended negative consequences of the FDA’s decision.

    Conclusions:

    • While the warning achieved its goal of raising awareness about the risks of antidepressants in children, it also resulted in under-treatment of depression, potentially exacerbating mental health challenges.
    • The article calls for balanced decision-making in pediatric antidepressant use, emphasizing the need for risk-benefit assessments and careful monitoring rather than outright avoidance of antidepressants.

      The FDA’s black box warning led to a reduction in antidepressant use but also to increased untreated mental illness, highlighting the complexities of addressing medication risks in vulnerable populations.

    1. Antidepressants and the Black Box Warning: Has Treatment Declined?

      Antidepressants and the Black Box Warning: Has Treatment Declined?

      The FDA’s black box warning on antidepressants highlights an increased risk of suicidal thoughts and behaviors, particularly in children, adolescents, and young adults during the early stages of treatment. However, while this warning raised concerns, it’s essential to understand its context:

      • The Risk: Antidepressants, especially SSRIs, can cause agitation or mood swings during the first few weeks of use, which may increase the risk of suicidal ideation. But studies have shown that untreated depression carries a far greater risk of suicide.
      • Impact on Treatment: Initially, the warning led to a reduction in prescriptions, especially for younger populations. However, there is now growing recognition that avoiding treatment for depression and anxiety can lead to worsened outcomes, including a higher risk of suicide.
      • Guidance: The black box warning does not mean antidepressants are dangerous for everyone. It is a reminder that careful monitoring during the first few weeks of treatment is essential. Psychotherapy combined with medication remains the most effective treatment for many.

      The takeaway: Antidepressants save lives, but starting treatment should always involve open communication between the patient and healthcare provider to manage risks and monitor progress closely.

    2. Psilocybin Outshines Escitalopram: A Breakthrough in Depression Treatment

      Psilocybin Outshines Escitalopram: A Breakthrough in Depression Treatment

      The article Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trialreports findings from an extended observation period on the comparative effects of psilocybin and escitalopram in treating depression. Here are the key points:

      Study Design: This was a 6-month follow-up of a Phase 2, double-blind, randomized controlled trial. It compared the effects of psilocybin (a psychedelic compound) and escitalopram (a common SSRI) on depression symptoms in patients with moderate-to-severe major depressive disorder (MDD).

      Participants: Patients with moderate-to-severe MDD were randomly assigned to either psilocybin or escitalopram groups. Both treatments were administered in a controlled clinical setting

      Primary Outcome: Depression symptom severity was measured using the QIDS-SR-16 (Quick Inventory of Depressive Symptomatology–Self-Report) scale at various time points, including baseline, during the treatment phase, and at the 6-month follow-up.

      Results:

      Both groups showed improvement in depression symptoms, but the psilocybin group had a greater reduction in symptoms compared to the escitalopram group.

      The effects of psilocybin were found to be more rapid and sustained over the 6-month period.

      Remission and Response Rates: A higher proportion of patients in the psilocybin group achieved remission and clinically significant response compared to those in the escitalopram group.

      Safety and Side Effects: Both treatments were generally well-tolerated. However, psilocybin was associated with transient, mild-to-moderate side effects, mostly during the acute phase of treatment (e.g., perceptual disturbances).

      Conclusion: Psilocybin demonstrated more pronounced and longer-lasting antidepressant effects compared to escitalopram at the 6-month follow-up. This suggests that psilocybin could be a viable alternative treatment for moderate-to-severe depression, but further research is necessary to confirm long-term safety and efficacy.

    3. Ketamine: A Temporary Fix, Not a Cure for Depression

      Ketamine: A Temporary Fix, Not a Cure for Depression

      It’s crucial to understand that ketamine is not a cure for depression. Many individuals experience a relapse, often within 2 to 4 weeks after finishing the initial treatment. If you’re expecting ketamine to fully resolve your depression, this could lead to disappointment and potentially harmful consequences.

    4. Doctor’s Near-Death Experience: The Truth Behind Antidepressant Withdrawal – Fact or Fiction

      Doctor’s Near-Death Experience: The Truth Behind Antidepressant Withdrawal – Fact or Fiction

      These sensational headlines about near-death experiences coming off antidepressants are becoming far too common. While we must be cautious with prescribing, it’s equally important not to dissuade people from trying medications that could help them.

      Yes, some patients experience withdrawal symptoms if medications are stopped abruptly without proper tapering. But many patients do not, and I’ve seen countless cases where people discontinue their antidepressants without any issues. Some may require prolonged tapers, while others can taper off much faster than alarmist articles would suggest.

      It’s crucial to remember that while discontinuation can be uncomfortable, it’s rarely life-threatening. We do need to be mindful of how long we prescribe these medications, given they manage symptoms but don’t modify the underlying disease, and the long-term benefits are still debated.

      Guidelines for deprescribing are helpful, but dramatic headlines about “nearly dying” when coming off these medications are not only inaccurate but harmful to those who could benefit from treatment. Let’s promote balanced, evidence-based discussion on this topic, focusing on proper discontinuation without sensationalizing the risks.

      Link to article: https://www.theguardian.com/australia-news/article/2024/jul/31/australian-doctor-mark-horowitz-who-almost-died-writes-landmark-guidance-on-how-to-safely-stop-using-antidepressants

    5. Surge in Antidepressant Overdoses Alarms Health Experts Across the U.S

      Surge in Antidepressant Overdoses Alarms Health Experts Across the U.S

      Rising Antidepressant Overdoses: A Growing Concern in the U.S.

      Recent data reveals that antidepressant overdoses in the U.S. have been steadily increasing from 1999 through 2022. According to a CDC report released last month, there were 5,863 overdose deaths attributed to antidepressants in 2022—numbers comparable to heroin-related fatalities, which claimed 5,871 lives. While these figures represent a small fraction of the over 100,000 overdose deaths that year—most of which involved fentanyl—they signal a troubling trend that demands attention.

      Potential Causes for the Rise in Antidepressant Overdoses

      Understanding the root causes of this increase is challenging, given the complexity of overdose data and the lack of detail on the exact substances involved. However, there are several factors worth considering.

      First, many individuals with opioid use disorder (OUD) also suffer from co-occurring mental health conditions like depression and bipolar disorder. These patients are often prescribed antidepressants, sometimes too liberally, in my experience working in community mental health. When opioids are mixed with antidepressants, opioids are often the primary cause of death in overdoses. Yet, I’ve also encountered numerous patients who have attempted suicide using antidepressants alone.

      Newer antidepressants are generally safer in overdose compared to older drugs, such as monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs). While these older medications tend to be more effective, they come with significantly higher risks in overdose situations. This is something I frequently emphasize to residents: older drugs are more dangerous, but the newer ones, though safer, can still have serious consequences.

      Chronic pain patients, who are often prescribed opioids, are another vulnerable group. Their risk of suicide is heightened by the constant pain they endure, and many of these individuals are also prescribed antidepressants like duloxetine, which is indicated for pain management, or more dangerous TCAs such as amitriptyline and nortriptyline. Additionally, gabapentin—another drug commonly prescribed to these patients—has been known to increase the risk of death when taken with opioids.

      Overprescription of Antidepressants: A Contributing Factor?

      There has also been a sharp rise in antidepressant prescriptions across the U.S., which I believe warrants scrutiny. Antidepressants are, at best, symptom management tools, with a modest effect size of 0.33 in many studies. Given these limited benefits, we should be more judicious about who we prescribe these medications to and for how long.

      Withdrawal symptoms from long-term—and sometimes even short-term—use of antidepressants can be severe, increasing the risk of suicide. I’ve personally seen this with a family member who experienced debilitating headaches and vertigo after stopping sertraline. She was unable to work or function for nearly two weeks, highlighting how challenging withdrawal can be for some patients.

      Balancing Risks and Benefits in Mental Health Treatment

      Any population for whom antidepressants are considered a treatment option is inherently at high risk for suicide. That said, there are many confounding factors in the overdose data, and mainstream mental health reporting often glosses over the nuances of psychiatric research and treatment. When prescribing medications, it’s crucial to weigh not only the pros and cons of the drugs themselves but also to tailor treatment to each individual’s unique needs.

      I continue to prescribe antidepressants to patients whom I’ve carefully evaluated and believe will benefit, even if only in the short term. However, I am transparent with them: antidepressants are unlikely to resolve deeper psychological conflicts or “problems of living.” Mental health is rarely black and white, and much of this uncertainty stems from our incomplete understanding of the brain.

      In short, we need to acknowledge the complexity behind the rise in antidepressant overdoses and respond with a more nuanced, patient-centered approach to prescribing these medications.

      Link to the article:

      https://www.theguardian.com/science/article/2024/sep/03/antidepressants-overdose-deaths-increasing